Safety and Tolerability of ShigActive™, a <i>Shigella</i> spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial

• Asıl Yazarlar: Wilbur H. Chen (Yazar), Joelle Woolston (Yazar), Silvia Grant-Beurmann (Yazar), Courtney K. Robinson (Yazar), Garima Bansal (Yazar), Joseph Nkeze (Yazar), Jasnehta Permala-Booth (Yazar), Claire M. Fraser (Yazar), Sharon M. Tennant (Yazar), Mallory C. Shriver (Yazar), Marcela F. Pasetti (Yazar), Yuanyuan Liang (Yazar), Karen L. Kotloff (Yazar), Alexander Sulakvelidze (Yazar), Jennifer A. Schwartz (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2024-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Bacterial diseases of the gastrointestinal (GI) tract continue to be a major worldwide cause of human morbidity and mortality. Among various enteric pathogens, <i>Shigella</i> spp. are some of the most common and deadly bacterial pathogens. They are responsible for ~125 million worldwide...